Barclays Issues Pessimistic Forecast for Zimmer Biomet (NYSE:ZBH) Stock Price

Zimmer Biomet (NYSE:ZBH) had its price target decreased by Barclays from $118.00 to $112.00 in a research report sent to investors on Monday,Benzinga reports. Barclays currently has an underweight rating on the medical equipment provider’s stock.

Several other research firms have also recently commented on ZBH. Raymond James lowered their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus raised their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Finally, Royal Bank of Canada dropped their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $98.98 on Monday. The firm has a market capitalization of $19.70 billion, a PE ratio of 22.24, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. Zimmer Biomet has a 1 year low of $97.69 and a 1 year high of $133.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.70. The firm’s 50-day moving average is $106.91 and its two-hundred day moving average is $107.91.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the company posted $2.20 EPS. Analysts predict that Zimmer Biomet will post 8.25 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds have recently modified their holdings of the business. Dunhill Financial LLC increased its position in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Stonebridge Financial Group LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $25,000. Ashton Thomas Securities LLC acquired a new position in shares of Zimmer Biomet in the third quarter valued at approximately $28,000. Brooklyn Investment Group purchased a new stake in shares of Zimmer Biomet during the third quarter worth approximately $35,000. Finally, Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $39,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.